GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2, PHASE3

The Lira Pump Trial

The Lira Pump Trial. The Effects of Liraglutide in Patients With Insulin Pump Treated Type 1 Diabetes: A Randomized Placebo-Controlled Trial

Lead sponsor

Hvidovre University Hospital

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, Type 1 diabetes

Key I/E criterion

•BMI ≥25

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02351232

Org study IDLPT2015

Secondary ID2014-002285-76

Timeline

Milestones

Study first posted2015-01-30estimated

Last update posted2020-02-12actual

Study start2015-02 (month precision)

Primary completion2016-10actual (month precision)

Study completion2016-10actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightType 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 1 diabetes ≥ 1 year

•BMI > 25 kg/m2

•Insulin pump ≥ 1 year

•HbA1c > 58 mmol/mol

•Use of carbohydrate counting and the insulin pump bolus calculator

Exclusion criteria

•Gastroparesis

•Impaired renal function (eGFR < 60 ml/min/1.73m2)

•Liver disease with ALAT > 2.5 times the upper limit of the reference interval

•Acute or chronic pancreatitis or history of chronic pancreatitis or idiopathic acute pancreatitis

•Inflammatory bowel disease

•History of cancer (except basal cell skin cancer) which in the investigators opinion could interfere with the results of the trial, or cancer during the past 5 years

•Thyroid adenoma

•Subjects with personal or family history of MTC or MEN2

•Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start

•Known or suspected alcohol or drug abuse

•Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation

•Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.

•Simultaneous participation in any other clinical intervention trial

•Known or suspected hypersensitivity to Liraglutide

•Inability to understand the patient information and to give informed consent

•Acute treatment required proliferative retinopathy or maculopathy (macular oedema)

•Any Cardiac disorder which in the investigators opinion could interfere with the safety and results of the trial.

Endpoints (13)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Cardiometabolic biomarkers

Patient-reported / QoL

Other (unclassified)

Renal / kidney

Safety / tolerability / PK

Weight & body composition

2 endpoints

Secondary/protocol endpoint

Change in weight

Time frame:6 months

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in body composition as measured by DXA-scan

Time frame:6 months

change from baseline, improvement

Glycemic / diabetes

3 endpoints

Primary/protocol endpoint

Change in HbA1c

Time frame:6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint/low confidence

Change in glucose variability as measured by continuous glucose monitoring

Time frame:6 months

change from baseline, improvement

Secondary/protocol endpoint

Number of daily blood glucose measurements

Time frame:6 months

descriptive

Renal / kidney

1 endpoint

Secondary/protocol endpoint

Change in kidney function as measured by urine albumine/creatinine ratio

Time frame:6 months

uACR, change

change from baseline, improvement

LOINC 9318-7

Cardiometabolic biomarkers

2 endpoints

Secondary/protocol endpoint

Change in blood pressure

Time frame:6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in lipid profile (LDL, HDL, VLDL, total cholesterol, triglycerides)

Time frame:6 months

change from baseline, improvement

Patient-reported / QoL

2 endpoints

Secondary/protocol endpoint

Change in treatment satisfaction as measured by Diabetes Treatment Satisfaction Questionnaire

Time frame:6 months

change from baseline, improvement

Secondary/protocol endpoint

Change in anxiety and depression as measured by Hospital Anxiety and Depression Scale

Time frame:6 months

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Frequency of hypoglycemia (patient reported number of episodes with blood glucose <3.9 mmol/l)

Time frame:6 months

Documented hypoglycemia

event count, event

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Change in insulin pump settings

Time frame:6 months

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in diet as measured by retrospective food recording

Time frame:6 months

change from baseline, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
Diabetes, obesity & metabolism2020 Apr (month)PMID31696598doi:10.1111/dom.13911via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.